Tier 4 — mechanistic

Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects

H. Viola, C. Wasowski, M. Levi de Stein, C. Wolfman, R. Silveira, F. Dajas, J. H. Medina, A. C. Paladini
Planta Medica 1995 61(3):213-216

Bibliography

PubMed
PMID 7617761
Funding
Not reported in the indexed record reviewed.
Competing interests
Not reported in the indexed record reviewed.

Study snapshot

DesignReceptor-binding experiments with acute mouse behavioral testing
ModelCentral benzodiazepine-receptor assays and mice
SampleExact total sample size was not reported in the PubMed abstract.
InterventionIsolated apigenin; receptor-binding assays and acute administration in mice across behavioral doses
DurationAcute preclinical experiments
EndpointsFlunitrazepam binding at central benzodiazepine receptors; Elevated plus-maze behavior; Locomotor activity; Hole-board behavior; Muscle relaxation; Anticonvulsant activity

What the study showed, in plain terms

This classic preclinical study identified apigenin from chamomile as a ligand at central benzodiazepine receptors and tested its behavioral effects in mice.

Key findings

Apigenin competitively inhibited flunitrazepam binding with a Ki of about 4 micromolar. In mice it produced anxiolytic-like behavior without obvious sedation or muscle relaxation at lower tested doses, while a ten-fold higher dose produced mild sedative effects.

What this study can and cannot tell us

The study is preclinical. Receptor affinity and mouse behavior do not establish that oral apigenin supplements treat anxiety or improve sleep in humans, and later pharmacology studies have reported more complex or conflicting GABA-receptor effects.

Citation network

Articles citing this research paper

3 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified